Onco Actu du 2 août 2018

	2.4 Etiologie - Portables, ondes e-m
Exposure to High-Frequency Electromagnetic Fields at Work Does Not Seem to Correlate with Higher Risk of Brain Tumours [ISGlobal] By assessing individual exposure to electromagnetic fields, INTEROCC represents the most comprehensive study in the field.
Electromagnetic Fields at Work Show No Brain Tumor Risk [Science-Based Medicine] A new study finds no significant correlation between workplace exposure to radio frequency (RF) or intermediate frequency (IF) electromagnetic waves and the most common brain tumors. This is more reassuring evidence that non-ionizing EMFs are probably safe.
	4.12 Biopsies liquides
Guardant Silent on TMB Plans, but Study Adds Evidence for Immunotherapy Prediction in Blood [Genome Web] The study focused on a group of 61 patients with advanced gastric cancer, treated with pembrolizumab (Merck's Keytruda) in a phase II trial. Investigators studied a variety of factors and their association with immunotherapy response including microsatellite instability (MSI) and PD-L1 expression, but also tumor mutational burden — more specifically, whether Guardant's 360 assay could recapitulate the same response prediction as tissue-based measurements of TMB.
	4.9 Dép., diag. & prono. - Sein
Breast Cancer Screening Market, Global Analysis by Population, Screening Tests [Mammography, MRI, Ultrasound] & Countries [ReportsnReports] Breast Cancer Screening Market is projected to reach US$ 21 Billion by the end of year 2024.
	5.1 Traitements - Pré-clinique
Novel Drug Cocktails Strengthen Targeted Cancer Therapies While Lessening Side Effects [Mount Sinai] The cocktails, which include chemotherapy, anti-tumor antibiotics, and chemical compounds, are given at low doses that would normally not give a therapeutic benefit on their own. Instead, they bolster a patient’s response to a separate targeted therapy drug, which blocks enzymes that help cancer cells grow.
	5.10 Traitements - Essais
How will a clinical trial called CHHiP affect the future of prostate radiotherapy? [Institute of Cancer Research] The CHHiP trial importantly found that having a higher dose of radiation, across fewer sessions was just as effective when treating prostate cancer and reduced the level of side effects. Previously patients needed to attend 37 appointments, every weekday across seven and a half weeks. The CHHiP trial brought this down to 20 sessions, taking just four weeks.
	5.12 Immunothérapies
Immunotherapy: How the Immune System Fights Cancer [NCI-YouTube] Immunotherapy uses the body’s immune system to fight cancer. This animation explains three types of immunotherapy used to treat cancer: nonspecific immune stimulation, T-cell transfer therapy, and immune checkpoint inhibitors.
	5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
CAR-T player Cell Medica names Kite’s European chief as CEO [FierceBiotech] Nowers joined Kite from Bristol-Myers Squibb in October 2016 with a brief to establish a commercial operation capable of handling the anticipated approval of CAR-T therapy Yescarta. After 22 months as Kite’s European leader, Nowers leaves the company as it closes in on the European approval of the CAR-T.
	5.2 Pharma
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML [Daiichi-Sankyo] The designation was granted based on the results of the pivotal phase 3 QuANTUM-R study of quizartinib, which were presented during the plenary program at the 23rd Congress of the European Hematology Association in June 2018. QuANTUM-R is the first randomized phase 3 study to show that a FLT3 inhibitor, quizartinib, prolongs overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory FLT3-ITD AML.
	5.2.1 Pharma - Partenariats
Novartis dispatches two more cancer drug castoffs to a partner in China [EndPoints] This isn’t their first deal. Novartis handed over a CYP17 inhibitor (CFG920), an oral androgen inhibitor to treat prostate cancer, in a pact they struck with the Chinese company last year.
Why we need to recognise the full spectrum of research commercialisation activities in academia [Institute of Cancer Research] The Institute of Cancer Research is influential on a national scale through its excellence in building partnerships with industry. Science Information and Policy Officer, Roya Ziaie, attended a conference to hear how academics can drive social and economic benefits through these partnerships.
	5.2.3 Pharma - économie
A slowing market—not new rivals—is hurting Pfizer's star cancer med Ibrance, executives say [FiercePharma] Pfizer and its peers have already persuaded the willing doctors out there to prescribe the new class, and the less-willing physicians “need more time to be convinced.”
	5.3 Traitements - FDA, EMA, NICE...
EU drugs agency sees 30 percent staff losses, more cuts in Brexit move [Reuters] “In the short- to mid-term EMA will have to reprioritize its resources to fully maintain its core activities related to the evaluation and supervision of medicines to the level of quality and within the timelines expected,” it said.
	6.1 Observation
Lung Cancer Mortality Rates Among Women Projected to Increase Worldwide By Over 40 Percent By 2030 [AACR] The global age-standardized breast cancer mortality rate is projected to decrease by 9 percent in the same time frame.
	6.11 Patients
Patients’ roles and rights in research [BMJ] Giving real power to patients and those who care for them will entail shaking up existing research hierarchies, not merely smoothing out a few bumps in current practice. Senior researchers should lead by example and embrace this essential culture change.
	6.12 Ethique
Series of ethical stumbles tests NIH’s reliance on private sector for research funding [STAT] The foundation, located down the road from the NIH’s campus in Bethesda, Md., is not technically a government entity, despite its congressional mandate. But in the last three decades it has facilitated hundreds of partnerships between the NIH and companies hoping to contribute to research, serving as an ethical clearinghouse between private donors and publicly funded researchers.
	6.4 Médico-éco
Childhood cancer survivors face ‘financial toxicity’ [Washington Post] New studies show a substantial percentage of cancer patients skip or delay needed care because of financial problems.
	6.6 Publications
Plan to replicate 50 high-impact cancer papers shrinks to just 18 [Science] “I wish we could have done more,” says biologist Tim Errington, who runs the project from the Center for Open Science in Charlottesville, Virginia. But, he adds, “There is an element of not truly understanding how challenging it is until you do a project like this.”
	6.7.2 Applis
Voluntis Announces The Launch Of Theraxium Oncology, An Innovative Digital Platform For Symptom Management [Voluntis] Theraxium Oncology takes advantage of over four years of research and development by Voluntis in partnership with life science partners and cancer institutes as well as user feedback from patients and multiple US cancer centers.
	6.9 Controverses
Court records show how a medical device ‘seeding trial’ disguised marketing as science [HealthNewsReviews] The Pinnacle seeding trial serves as another reminder for consumers to be wary of medical devices, particularly those devices that are new to the market. Few undergo rigorous trials before they are sold, and there are often cozy ties between doctors and device industry sales representatives.